Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 8K | 3M | 1M | 2M |
| Gross Profit | 0 | 8K | 3M | 1M | 2M |
| Operating Income | -4M | -41M | -55M | -67M | -61M |
| EBITDA | -4M | -22M | -55M | -64M | -58M |
| Net Income | -1M | -23M | -57M | -66M | -61M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.71
+0.00% today
1Y Change
-36.75%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Synlogic, Inc. (SYBX) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.71 and down 36.8% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +95.8%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +95.8%, free cash flow +86.2% with operating margin 0.0% and ROIC -33.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYBX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYBX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYBX Max Drawdown
-69.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYBX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.8M
+48.6% YoY
FY Net Income
-$60.6M
+8.4% YoY
Free Cash Flow
-$52.9M
+8.2% YoY
Revenue Growth
-100.0%
EPS Growth
+95.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 8K | 3M | 1M | 2M |
| Gross Profit | 0 | 8K | 3M | 1M | 2M |
| Operating Income | -4M | -41M | -55M | -67M | -61M |
| EBITDA | -4M | -22M | -55M | -64M | -58M |
| Net Income | -1M | -23M | -57M | -66M | -61M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15M | 19M | 24M | 16M | 16M |
| Total Assets | 15M | 20M | 76M | 111M | 175M |
| Total Liabilities | 4M | 7M | 33M | 28M | 27M |
| Shareholder Equity | 12M | 13M | 43M | 83M | 147M |
| Total Debt | 0 | 0 | 17M | 20M | 21M |
| Net Debt | -15M | -19M | -7M | 4M | 4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
52M
+8.2% YoY
Capital Expenditures
679K
+6.7% YoY
Free Cash Flow
53M
+8.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-8.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.